HIV Drugs May Treat Prostate Cancer and Chronic Fatigue Syndrome

.

HIV Drugs May Treat Prostate Cancer and Chronic Fatigue Syndrome

University of Utah and Emory University/Veterans Affair Medical Center (VA) conducted a research which concluded that retrovirus associated to chronic fatigue syndrome (CFS) and prostate cancer has been found to be present in four drugs that are used to combat HIV.

The research has raised a hope that if it is found that retrovirus XMRV i. e., Xenotropic murine leukemia virus-related virus causes prostate cancer or CFS; the HIV drugs can prove helpful in curing the same.

Dr. Ila R Singh said that the concluded results were a ray of hope for the patients suffering from prostate cancer and CFS.

The researchers will have to look for a better and magnified understanding of the links between HIV and CFS and prostate cancer for developing drugs that can cure them.

In this research, in cultured human breast cancer and prostate cancer cells, 45 drugs treating HIV were tested for their effectiveness against XMRV.

Raltegravir, L-00870812, Zidovudine and Tenofovir disoproxil fumarate were the drugs tested.

Co-investigator Raymond F Schinazi said that the research revealed that drugs inhibited XMRV at lower levels when used together, which in turn indicate that the virus might restrain the virus from replicating and spreading.


Latest News

Shares of Coca-Cola Drop as Sales Remain Sluggish
Target Makes an Effort to Win Over Shoppers with Free Shipping
Agreement between Amazon.com and Simon & Schuster to be Advantageous for Both th
Nadella gets a Pay Package Worth $84M from Microsoft; Announces Help in Ebola Re
Slowest Growth in China since the 2008/9 Global Crisis
New Models of iPhone Helps Apple to Achieve a Record Profit
Reheating pasta makes it healthier
Google Glass’ first addict
High-fat meals can cause obesity in men before women
Fujifilm shares go up after Ebola drug announcement
QEP Pipeline Assets Bought by Tesoro in a $2.5 Billion Deal
Adidas’s Reebok to Get a $2.2 billion Bid from Investors